Us Bancorp \De\ Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Us Bancorp \De\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$144.95 - $152.29 $82,331 - $86,500	-568 Reduced 64.99%	306 $46,000
Q2 2022 Aug 01, 2022	BUY	$83.14 - $145.99 $23,944 - $42,045	288 Added 49.15%	874 $127,000
Q1 2022 May 11, 2022	BUY	$110.08 - $142.92 $10,347 - $13,434	94 Added 19.11%	586 $70,000
Q4 2021 Feb 11, 2022	BUY	$99.73 - $148.48 $41,986 - $62,510	421 Added 592.96%	492 $68,000
Q3 2021 Nov 10, 2021	BUY	$98.85 - $138.91 $6,128 - $8,612	62 Added 688.89%	71 $10,000
Q2 2021 Aug 05, 2021	SELL	$65.78 - $105.02 $263 - $420	-4 Reduced 30.77%	9 $1,000
Q1 2021 Apr 28, 2021	SELL	$64.07 - $91.75 $17,362 - $24,864	-271 Reduced 95.42%	13 $1,000
Q4 2020 Feb 04, 2021	BUY	$65.07 - $98.24 $18,479 - $27,900	284 New	284 $25,000
Q1 2020 May 13, 2020	SELL	$27.51 - $57.29 $275 - $572	-10 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$37.38 - $49.47 $10,391 - $13,752	-278 Reduced 96.53%	10 $0
Q2 2019 Aug 13, 2019	BUY	$39.79 - $67.01 $9,310 - $15,680	234 Added 433.33%	288 $12,000
Q1 2019 May 08, 2019	BUY	$34.52 - $53.29 $1,864 - $2,877	54 New	54 $3,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.